Prosecution Insights
Last updated: November 12, 2026
Application No. 18/729,525

METHODS AND SYSTEMS FOR EVALUATION OF TISSUE SAMPLES

Non-Final OA §102§103§112
Filed
Jul 17, 2024
Priority
Jan 19, 2022 — provisional 63/301,038 +2 more
Examiner
MCGUIRK, JOHN SCHUYLER
Art Unit
1798
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Empiri Inc.
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
182 granted / 234 resolved
+12.8% vs TC avg
Strong +48% interview lift
Without
With
+48.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
37 currently pending
Career history
275
Total Applications
across all art units

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . REQUIREMENT FOR UNITY OF INVENTION As provided in 37 CFR 1.475(a), a national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept (“requirement of unity of invention”). Where a group of inventions is claimed in a national stage application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression “special technical features” shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art. The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim. See 37 CFR 1.475(e). When Claims Are Directed to Multiple Categories of Inventions: As provided in 37 CFR 1.475 (b), a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories: (1) A product and a process specially adapted for the manufacture of said product; or (2) A product and a process of use of said product; or (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or (4) A process and an apparatus or means specifically designed for carrying out the said process; or (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process. Otherwise, unity of invention might not be present. See 37 CFR 1.475 (c). Restriction is required under 35 U.S.C. 121 and 372. This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted. Group I, claim(s) 1-11, drawn to systems and methods for processing a live tissue sample comprising a blade. Group II, claim(s) 12-17, drawn to systems for processing a live tissue sample comprising a funnel-shaped structure. Group III, claim(s) 18-23, drawn to systems for processing a live tissue sample comprising a ring. Group IV, claim(s) 24-26, drawn to systems for processing a live tissue sample comprising at least one column. The groups of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups I-IV lack unity of invention because even though the inventions of these groups require the technical feature of a system for processing a live tissue sample comprising: a well plate; and a filter, this technical feature is not a special technical feature as it does not make a contribution over the prior art in view of Sawyer et al. (US Pub. No. 2020/0354668; hereinafter Sawyer). Sawyer teaches a system for processing a live tissue sample ([0279], see Fig. 1) comprising: a well plate; and a filter ([0176]-[0177], see Fig. 1 at well plate 110, and filter material 122 compressed between well plate 110 and center plate 120). During a telephone conversation with Lawrence Sung on 10/22/2026 a provisional election was made without traverse to prosecute the invention of Group I, claims 1-11. Affirmation of this election must be made by applicant in replying to this Office action. Claims 12-26 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention. The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention or species. Should applicant traverse on the ground that the inventions have unity of invention (37 CFR 1.475(a)), applicant must provide reasons in support thereof. Applicant may submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. Where such evidence or admission is provided by applicant, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103 or pre-AIA 35 U.S.C. 103(a) of the other invention. Applicant is reminded that upon the cancelation of claims to a non-elected invention, the inventorship must be corrected in compliance with 37 CFR 1.48(a) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. A request to correct inventorship under 37 CFR 1.48(a) must be accompanied by an application data sheet in accordance with 37 CFR 1.76 that identifies each inventor by his or her legal name and by the processing fee required under 37 CFR 1.17(i). Claim Status Claims 1-26 are pending, with claims 1-11 being examined, and claims 12-26 deemed withdrawn. Information Disclosure Statement The information disclosure statement (IDS) received on 7/17/2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. This application includes one or more claim limitations that do not use the word “means,” but are nonetheless being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because the claim limitation(s) uses a generic placeholder that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier. Such claim limitation(s) is/are: “an indexing mechanism configured to move the live tissue sample in precise increments” in claim 1. Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof. A review of the specification shows that the following appears to be the corresponding structure described in the specification for the 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph limitation: [0011] of the Pre-Grant Publication of the instant Application, US Pub. No. 2025/0172460 (Workman et al., hereinafter “Workman”) teaches the indexing mechanism being a linear actuator. For purposes of examination, the examiner will interpret the indexing mechanism to be a linear actuator, and equivalents thereof. If applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. For more information, see MPEP § 2173 et seq. and Supplementary Examination Guidelines for Determining Compliance With 35 U.S.C. 112 and for Treatment of Related Issues in Patent Applications, 76 FR 7162, 7167 (Feb. 9, 2011). Examiner’s Note: Claim 2 provides sufficient structure for the indexing mechanism to not require an interpretation under 112(f). Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The term “precise increments” in claim 1 is a relative term which renders the claim indefinite. The term “precise increments” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. It is unclear what distance the indexing mechanism must be configured to move the live tissue sample that would be considered a “precise increment”. Claims 2-8 are rejected at least for depending on a rejected claim. Claim 8 recites the limitation "the device" in Ln. 2. There is insufficient antecedent basis for this limitation in the claim. For purposes of compact prosecution, the above limitation has been examined as “the system”. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1 and 4-7 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Miyatani et al. (Translation of JP Pub. No. 2008-164458; hereinafter Miyatani). Regarding claim 1, Miyatani discloses a system for processing a live tissue sample (Pg. 3 5th Para., Pg. 6 Last Para.-Pg. 7 First Para., see Fig. 1). The system comprises: a sample holder configured to receive a live tissue sample (Pg. 6 3rd to Last Para.-Pg. 7 2nd to Last Para., see Fig. 1 at cassette K). A bracket configured to receive the sample holder (Pg. 6 3rd to Last Para.-Pg. 7 2nd to Last Para., see Fig. 1 at height stage 12). An indexing mechanism configured to move the live tissue sample in precise increments (Pg. 6 3rd to Last Para.-Pg. 7 2nd to Last Para., see Fig. 1 at moving stage 11, which is reciprocated on a guide rail 10 by a motor. See the Claim Interpretation in the instant Office Action above, which states that the indexing mechanism has been interpreted under 112(f) as a linear actuator, and equivalents thereof). A blade operatively connected to the sample holder that is configured to cut the live tissue sample (Pg. 6 3rd to Last Para.-Pg. 7 2nd to Last Para., see Fig. 1 at cutting blade 2). Note: The instant Claims contain a large amount of functional language (ex: “configured to receive a live tissue sample…”, “configured to receive the sample holder…”, “configured to move the live tissue sample in precise increments”, etc.). However, functional language does not add any further structure to an apparatus beyond a capability. Apparatus claims must distinguish over the prior art in terms of structure rather than function (see MPEP 2114). Therefore, if the prior art structure is capable of performing the function, then the prior art meets the limitation in the claims. Regarding claim 4, Miyatani discloses the system of claim 1, further comprises a cutting surface configured to receive a controlled amount of fluid sufficient to lubricate the cutting surface and the live tissue sample, wherein the indexing mechanism is operatively connected to the cutting surface (Pg. 8 1st Para.-2nd to Last Para., see Fig. 1 at spraying unit 24, where sprayed water from the spraying unit adheres to the conveyance belt 20 for transporting thin slice M from cutting blade 2). Regarding claim 5, Miyatani discloses the system of claim 4, wherein the fluid is provided in the form of a mist having at least one droplet (Pg. 4 3rd to Last Para., Pg. 8 1st Para.-2nd to Last Para.). Regarding claim 6, Miyatani discloses the system of claim 4, further comprising: a receptacle operatively connected to the sample holder that is configured to receive a section of the live tissue sample after the section is cut by the blade (Pg. 6 2nd to Last Para., see Fig. 1 at liquid tank 4). Regarding claim 7, Miyatani discloses the system of claim 6, wherein the receptacle is positioned to contact the fluid (Pg. 4 3rd to Last Para., Pg. 6 2nd to Last Para., Pg. 8 1st Para.-2nd to Last Para., see Fig. 1 at liquid tank 4). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 2-3 are rejected under 35 U.S.C. 103 as being unpatentable over Miyatani, as applied to claims 1 and 4-7 above, in view of Kong et al. (US Pat. No. 7,146,895; hereinafter Kong; already of record on the IDS received 7/17/2024). Regarding claim 2, Miyatani discloses the system of claim 1, and all limitations recited therein. Miyatani fails to explicitly disclose that the indexing mechanism comprises a linear actuator that comprises a plunger configured to move the live tissue sample towards the blade. Kong is in the analogous field of specimen cutting devices (Kong Col. 1 Lns. 36-56). Kong teaches an indexing mechanism that comprises a linear actuator that comprises a plunger configured to move a live tissue sample towards a blade (Kong; Col. 1 Ln. 36-Col. 2 Ln. 9, Col. 3 Ln. 14-Col. 4 Ln. 47, see Fig. 3 at specimen 148 on plunger 140 of syringe 130). It would have been obvious to one having ordinary skill in the art before the effective filing date of the invention to modify the system of Miyatani with the teachings of Kong so that the indexing mechanism comprises a linear actuator that comprises a plunger configured to move the live tissue sample towards the blade, in order to control the thickness of the slices cut from the specimen by the axial movement of the plunger (Kong; Col. 1 Ln. 36-Col. 2 Ln. 9, Col. 3 Ln. 14-Col. 4 Ln. 47, see Fig. 3). Regarding claim 3, modified Miyatani discloses the system of claim 2. Modified Miyatani fails to explicitly disclose that the live tissue sample is moved from about 200 micrometers to about 400 micrometers. However, Kong teaches live tissue sample that is moved incrementally on a micrometer scale (Kong Col. 4 Lns. 35-47). It would have been obvious to one having ordinary skill in the art before the effective filing date of the invention to modify the system of modified Miyatani so that the live tissue sample is moved from about 200 micrometers to about 400 micrometers, since where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. See In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955), and MPEP 2144.05(II)(A). The motivation would have been to optimize the thickness of the slices of the live tissue samples for subsequent use. Claim 8 is rejected under 35 U.S.C. 103 as being unpatentable over Miyatani, as applied to claims 1 and 4-7 above, in view of Magavi et al. (US Pub. No. 2013/0019725; hereinafter Magavi). Regarding claim 8, Miyatani discloses the system of claim 1. Miyatani further discloses that the system is configured for automated operation with no more than one single live tissue sample (Col. 3 3rd-6th Paras., Pg. 6 3rd to Last Para.-Pg. 7 1st Para., see Fig. 1, where a single sample is in an embedding block B). Miyatani fails to explicitly disclose a user interface. Magavi is in the analogous field of tissue sample processing (Magavi [0006]). Magavi teaches a user interface (Magavi [0037]). It would have been obvious to one having ordinary skill in the art before the effective filing date of the invention to modify the system of Miyatani with the teachings of Magavi so that the system comprises a user interface, so that a user can set parameters for automated control of the system (Magavi [0037]). Claims 9-10 are rejected under 35 U.S.C. 103 as being unpatentable over Kokubo (US Pat. No. 7,811,518) in view of Folch et al. (US Pub. No. 2022/0362765; hereinafter Folch). Regarding claim 9, Kokubo discloses a method of processing a live tissue sample (Col. 1 Lns. 15-27). The method comprises: providing an assembly that is operatively connected to a blade (Col. 5 Ln. 54-Col. 6 Ln. 39, see Figs. 1, 5 at knife 22, where a specimen slice 41 is transferred from carrier tape 5 onto a glass slide through contact of a water droplet 43). Cutting the live tissue sample with the blade (Col. 5 Ln. 54-Col. 6 Ln. 39, see Figs. 1, 5). Obtaining a section of the live tissue sample (Col. 5 Ln. 54-Col. 6 Ln. 39, see Figs. 1, 5). Kokubo fails to explicitly disclose that the assembly is a well plate comprising a filter assembly. Folch is in the analogous field of devices for trapping tissue samples (Folch [0007]). Folch teaches a well plate comprising a filter assembly (Folch; [0075], [0113], [0129]). It would have been obvious to one having ordinary skill in the art before the effective filing date of the invention to modify the assembly in the method of Kokubo to be a well plate comprising a filter assembly as in Folch, as Folch teaches that a well plate comprising a filter assembly can be used to culture a tissue sample (Folch; [0075], [0113], [0129]). Regarding claim 10, modified Kokubo discloses the method of claim 9. Modified Kokubo further discloses: contacting the live tissue sample with a fluid configured to generate a droplet of the fluid sufficient to lubricate the live tissue sample; contacting the droplet with the filter assembly; and contacting the section of the live tissue sample with the droplet contacted filter assembly (Kokubo; Col. 5 Ln. 54-Col. 6 Ln. 39, see Figs. 1, 5 at knife 22, where a specimen slice 41 is transferred from carrier tape 5 onto a glass slide through contact of a water droplet 43 (i.e. the water film). Further, see Claim 9 above at Folch teaching the filter assembly in [0075], [0113], [0129]). Claim 11 is rejected under 35 U.S.C. 103 as being unpatentable over Kokubo in view of Folch as applied to claims 9-10 above, and further in view of Magavi. Regarding claim 11, modified Kokubo discloses the method of claim 9. Modified Kokubo fails to explicitly disclose providing a user interface operatively connected to a device configured to perform the steps of the method in an automated operation with no more than one single live tissue sample. Magavi is in the analogous field of tissue sample processing (Magavi [0006]). Magavi teaches providing a user interface operatively connected to a device configured to perform the steps of the method in an automated operation with no more than one single live tissue sample (Magavi; [0037], see Fig. 2, which shows a single tissue sample). It would have been obvious to one having ordinary skill in the art before the effective filing date of the invention to modify the method of modified Kokubo with the teachings of Magavi to comprise providing a user interface operatively connected to a device configured to perform the steps of the method in an automated operation with no more than one single live tissue sample, so that the system comprises a user interface, so that a user can set parameters for automated control of the system (Magavi [0037]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to John McGuirk whose telephone number is (571)272-1949. The examiner can normally be reached M-F 8am-530pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Charles Capozzi can be reached at (571) 270-3638. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOHN MCGUIRK/Primary Examiner, Art Unit 1798
Read full office action

Prosecution Timeline

Jul 17, 2024
Application Filed
Oct 22, 2025
Response after Non-Final Action
Oct 28, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12791463
METHOD AND APPARATUS TO DETERMINE THE AMOUNT OF CARBONATE IN A BIOMINERALIZED CACO3
2y 10m to grant Granted Nov 10, 2026
Patent 12716905
AUTOMATIC ANALYZER AND SEPARATION COLUMN INSTALLATION METHOD FOR SAME
3y 12m to grant Granted Aug 25, 2026
Patent 12709727
DEVICES AND METHODS FOR INCREASING THROUGHPUT OF FLOW-BASED ELECTROPORATION SYSTEMS
3y 10m to grant Granted Aug 18, 2026
Patent 12710437
SPECIMEN TESTING SYSTEM, RACK TRANSPORTATION SYSTEM, RACK TRANSPORTATION CONTROL DEVICE, AND RACK TRANSPORTATION METHOD
3y 7m to grant Granted Aug 18, 2026
Patent 12702130
CELL CRYOPRESERVATION DEVICE
3y 7m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
99%
With Interview (+48.0%)
Low
PTA Risk
Based on 234 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month